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Genomic imprinting is an epigenetic feature that plays a significant role in carcinogen-
esis.  In this study, we examined the expression status of an imprinted gene, paternally ex-
pressed gene 1/mesoderm-specific transcript (PEG1/MEST), in 38 cases of head and neck 
squamous cell carcinomas (HNSCCs) and in 17 oral squamous cancer cell lines.  Loss of 
imprinting (LOI) of PEG1/MEST was found in 8 of 10 (80%) in tumor specimens, and 6 of 
10 (60%) informative cases even in the extracted normal tissue specimens.  As for the oral 
squamous cancer cell lines, LOI was detected in 5 of 8 (62.5%) informative cases in PEG1/
MEST.  Thus, these data showed that abnormal expression of PEG1/MEST was found at a 
high frequency in the tumor, the extracted normal tissue specimens and the oral squamous 
cancer cell lines.  PEG1/MEST LOI in extracted normal tissue specimens may have a po-
tential individual cancer risk for HNSCC.
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Head and neck cancers are almost always squamous 
cell types arising in the oral cavity, tongue, pharynx 
and larynx.  Understanding the molecular mecha-
nisms involved in tumor development and progres-
sion has enabled the design of new biological ap-
proaches.  This study focuses on molecular studies 
on the roles of genomic imprinting.  Almost all im-
printed genes identified to date can be classified as 
regulators of embryonic growth, placental growth 
or adult metabolism (Morison et al., 2005).  Mono-
allelic expression of either the maternal or paternal 
copy occurs while the other copy is silenced in nor-
mal somatic tissue specimens.  Imprinted genes are 
often clustered in chromosomal domains and are 
thought to be coordinately regulated by imprinting 
control centers. More than 60 types of imprinted 
genes have been identified in humans (Delaval and 
Feil, 2004).
 Mutations that affect the epigenetic states of 
imprinted domains underlie a number of human 
diseases (Walter and Paulsen, 2003).  Loss of im-
printing (LOI) is one of the most frequent alterations 
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found in cancers and involves abnormal activation 
of a normally silent allele.  Jaenisch and colleagues 
have demonstrated that global LOI leads to tumor 
formation in chimeric mice.  All the tumors in the 
mice were derived from non-imprinted cells.  Most 
importantly, tumors were not seen in the offspring of 
the chimaeras, as imprinting is reset during gameto-
genesis (Goymer, 2005).
 Imprinting is therefore an epigenetic tumor-
suppressing phenomenon.  When imprinting is lost, 
cells are immortalized through the inappropriate 
regulation of both tumor suppressors and oncogenes 
(Holm et al., 2005).  The genes exhibiting LOI in 
human cancer leading to biallelic expression has 
been reported in a variety of tumors including head 
and neck squamous cell carcinomas (HNSCCs) 
(Schofield et al., 2001; Feinberg and Tycko, 2004). 
Previous studies regarding imprinted genes in 
HNSCC suggested that LOI of IGF2, H19 and 
p57KIP2 loci play an important role in oncogenesis 
(el-Naggar et al., 1999; Lai et al., 2000; Rainho et al., 
2001).  However, the involvement of other imprinted 
genes is still poorly understood in HNSCC. 
 Paternally expressed gene 1/mesoderm-
specific transcript (PEG1/MEST) is a paternally 
expressed gene located on human chromosome 
7q32 (Kobayashi et al., 1997).  PEG1/MEST LOI 
has been reported in lung cancers (Suda et al., 2003; 
Nakanishi et al., 2004), breast cancers (Pedersen et 
al., 1999, 2002) and colorectal cancers (Nishihara et 
al., 2000).  In these previous studies, it was postulated 
that the disruption of PEG1/MEST might be impli-
cated in the etiology of these cancers.  In this study, 
we examined the imprinting status of PEG1/MEST 
in HNSCC specimens and oral squamous cancer cell 
lines with special attention to the role of PEG1/MEST 
LOI on oncogenesis in HNSCC tissue specimens and 
several oral squamous cancer cell lines.
 
Materials and Methods
 
Tissue samples
 
HNSCCs, diagnosed by histopathologic examina-
tion and matched with extracted normal tissue 
specimens from 38 patients, were analyzed in this 
study.  They consisted of 16 oral cancers, 4 oropha-
ryngeal cancers, 5 hypopharyngeal cancers and 
13 laryngeal cancers.  All tissue specimens were 
obtained during surgery at the Clinical Depart-
ment of Otolaryngology, Head and Neck Surgery, 
Tottori University Hospital.  Each resected tumor 
was carefully trimmed to remove normal tissue. 
Then extracted normal tissue was selected as far 
from the cancerous areas as possible.  We usually 
picked extracted normal tissue from the muscle, 
which was removed when neck dissections were 
performed.  Informed consent to participate in this 
study was obtained from each patient.  The institu-
tional review board of Tottori University approved 
this study (approval number 746).  All tissue speci-
mens were stored at –80°C until analysis.
Cell lines
 
Seventeen oral squamous cancer cell lines were 
analyzed.  HSC-2, HSC-3 and HSC-4 were es-
tablished and provided by Uzawa and associates 
(Uzawa et al., 1995).  HO-1-N-1, HO-1-u-1, KON, 
KOSC-2 cl3-43, OSC-19, OSC-20, SCC-4 and 
SKN-3 were obtained from the Japanese Collection 
of Research Bioresources (Osaka, Japan).  SAS 
were obtained from the Cell Resource Center for 
Biomedical Research, Tohoku University (Sendai, 
Japan).  Eight oral squamous cancer cell lines 
(HSC-2, HSC-3, HSC-4, HSC-5, HSC-6, HSC-
7, KON and SCCKN) were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) with 10% fe-
tal bovine serum.  Two (HO-1-N-1 and HO-1-u-1) 
were grown in DMEM-F12 medium (1:1 mix) with 
10% fetal bovine serum.  Two (OSC-19 and OSC-
20) were grown in DMEM-F12 medium (1:1 mix) 
without serum.  SCC-4 was grown in DMEM-F12 
medium (1:1 mix) with 10% fetal bovine serum and 
0.4 µg/mL hydrocortisone.  Four (KOSC-2 cl3-43, 
SAT, SAS and SKN-3) were grown in RPMI 1640 
medium with 10% fetal bovine serum.  These cells 
were cultured and growing cells with 70% conflu-
ence were harvested for analyses.
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DNA and RNA sample preparation
 
Genomic DNA was isolated using a Puregene 
DNA Isolation Kit (Gentra Systems, Minneapolis, 
MN).  Total RNA was isolated using an RNeasy 
Kit (QIAGEN, Valencia, CA) according to the 
manufacturer’s instructions.  Total RNA was 
treated with RNase-free DNase I (Takara Bio, 
Shiga, Japan) to remove any DNA contamination. 
First-strand cDNA synthesis was carried out with 
or without SuperScript III Reverse Transcriptase 
(RT+ or –) (Invitrogen, Carlsbad, CA) by using an 
oligo (dT)15 primer (Roche, Basel, Switzerland). 
The sequences of the primers were 5-CACTGAT-
GCAGAAAGACGTTC-3 and 5-CAGCACCAT 
TTGCTCATAGG-3.
 
Identification of polymorphisms
 
Imprinting analysis for PEG1/MEST was car-
ried out by single nucleotide polymorphism (SNP) 
analysis for informative heterozygotes at the G/A 
(exon 12; rs10863) polymorphism.  An informative 
DNA polymorphism at an AflIII site was identified 
as the AflIII-digestible (ACACGT) or indigestible 
(ACACAT) sequence.  PCR was performed for 30 
cycles including denaturation at 95˚C for 30 s, an-
nealing at 62˚C for 30 s and extension at 72˚C for 30 s.
 
Allele-specific expression analysis
 
Allele-specific expression analysis with RT-PCR 
and digestion by restriction enzymes was per-
formed under the same conditions as those used to 
detect genomic polymorphisms.  To confirm the 
results of restriction fragment length polymorphism 
(RFLP), we also performed a method for allele-
specific expression analysis of imprinted genes by 
real-time PCR with Cycling Probe Technology 
(Takara Bio).  In this method, one end of the probe 
is labeled with a fluorescent substance and the other 
end is labeled with a quencher, which quenches the 
fluorescence emitted from the substance.  RNaseH 
specificially cuts the RNA region of this probe, 
resulting in emission of strong fluorescence, but it 
does not cut the RNA probe region including any 
mismatches.
  
 
Results
 
We analyzed 38 primary HNSCCs for the LOI in 
PEG1/MEST.  First of all we identified genomic 
polymorphisms using RFLP analysis.  Informative 
cases were then further analyzed to determine their 
allele-specific expression.  As shown in Figs. 1 and 
2, we distinguished the 2 alleles and determined 
whether a case is informative or not.  This poly-
morphism (G/A; rs10863) results in the presence 
Fig. 1.
A:  A schematic of the AflIII polymorphism of human PEG1/MEST is shown.  The arrow indicates the site of the polymor-
phism.  PCR products contain this polymorphic site.  A-a represents the undigested product (792 bp) and A-b represents 
product digested with AflIII (383 and 409 bp).  PEG1/MEST, paternally expressed gene 1/mesoderm-specific transcript. 
B:  Heterozygosity called informative is necessary for allele-specific analysis.
  Extracted specimen
Genome Normal   Tumor
 + – + –
Case 1Case 4
 Imprinted LOI  LOI LOI
792
409 
383
792
409 
383
  Extracted specimen
Genome Normal   Tumor
 + – + –(bp) (bp)
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or absence of an AflIII site.  The 3 different bands 
(792, 409 and 383 bp) after AflIII digestion of the 
genomic PCR fragment indicated an informative 
heterozygous case.  Next, to determine the expres-
sion status of PEG1/MEST, the RT-PCR products 
are digested with AflIII to determine whether one 
or both copies are expressed.  The presence of 3 
bands indicates biallelic expression, that is, PEG1/
MEST LOI.  On the other hand, a single band of 
792 bp or 2 bands of 409 bp and 383 bp showed 
monoallelic expression, indicating the normal im-
printing status of PEG1/MEST.  Among the cases 
screened, we observed 10 informative cases of 
PEG1/MEST.  PEG1/MEST LOI was found in 8 
informative cases (80%), and in 6 cases (60%) it 
was detected even in the normal tissue specimens 
(Table 1), regardless of tumor location or histology. 
These data suggest that PEG1/MEST LOI occurs 
in HNSCC specimens, suggesting its fundamental 
role in HNSCC oncogenesis.
 Next, we analyzed the imprinting status of 
PEG1/MEST in 17 oral squamous cancer cell lines 
to substantiate the results from the tissue specimens. 
The results for the histopathologic types of these 
oral squamous cancer cell lines are summarized in 
Table 2.  PEG1/MEST LOI was observed in 5 of 8 
informative cases (62.5%).  The results from the cell 
lines are summarized in Table 2, which were con-
sistent with the high frequency of LOI at the PEG1/
MEST loci detected in the HNSCC tissue speci-
mens.  Thus, abnormal expression of PEG1/MEST 
was found at a high frequency in the cancer tissue 
specimens, the extracted normal tissue specimens 
and the oral squamous cancer cell lines.
Fig. 2.  Allele-specific expression analysis of PEG1/MEST in head and neck squamous cell carcinoma tissue specimens.  The 
allele-specific expressions of PEG1/MEST were assessed by restriction fragment length polymorphism analysis.  Representa-
tive results of PEG1/MEST are shown.  +, presence of reverse transcriptase (RT); –, absence of RT; LOI, loss of imprinting; 
PEG1/MEST, paternally expressed gene 1/mesoderm-specific transcript.
Table 1.  Summary of PEG1/MEST gene expression profiles in informative cases of tissue speci-
mens of head and neck squamous cell carcinoma 
  Case         Type of cancer Histological classification               PEG1/MEST
number   Normal Tumor
     1 Tongue cancer Moderately differentiated LOI LOI
     2  Laryngeal cancer Moderately differentiated LOI LOI
     3  Laryngeal cancer Well differentiated LOI LOI
     4  Hypopharyngeal cancer Poorly differentiated Imprinted LOI
     5  Tongue cancer Well differentiated Imprinted Imprinted
     6  Tongue cancer Moderately differentiated Imprinted LOI
     7  Tongue cancer Moderately differentiated Imprinted LOI
     8  Laryngeal cancer Moderately differentiated LOI LOI
     9  Oropharyngeal cancer Moderately differentiated LOI LOI
   10  Laryngeal cancer Poorly differentiated LOI Imprinted
LOI, loss of imprinting; PEG1/MEST, paternally expressed gene 1/mesoderm-specific transcript.
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Discussion
 
Several lines of evidence suggest that the disrup-
tion of imprinting mechanisms play a critical role 
in oncogenesis including HNSCC, but none have 
examined PEG1/MEST in HNSCC.  The data from 
mice studies of Mest have suggested a possible 
role of Mest as a regulator of embryonic growth. 
Mest paternal knockouts have been shown to result 
in an imprinted phenotype characterized by fetal 
and placental growth retardation (Lefebvre et al., 
1998).  In our report, we provide the first evidence 
regarding the presence of biallelic expression of 
PEG1/MEST in HNSCC.  PEG1/MEST LOI was 
identified 8 out of 10 cases in HNSCC tissue speci-
mens and 5 out of 8 cases in oral cancer cell lines. 
Interestingly, PEG1/MEST LOI was observed in 
the extracted normal tissue surrounding the tumor 
specimens.
 IGF2 and PEG1/MEST are known as im-
printed genes important in fetal growth.  The cor-
relation between IGF2 LOI in normal cells and 
colorectal cancer has been well documented (Cui 
et al., 2003; Nakano et al., 2006).  IGF2 LOI has 
been found in 10% of normal individuals (Sakatani 
et al., 2001) and it appears to be 5 times more 
common in patients with a family history of colon 
carcinoma, and 21 times more common in patients 
with a personal history of colorectal neoplasia (Cui 
et al., 2003).  Moreover, a mouse model with Igf2 
LOI suggests that mice with abnormal imprinting 
acquired twice as many intestinal adenomas as 
those whose imprinting was normal (Sakatani et 
al., 2005).  These studies indicated that IGF2 LOI 
might be a valuable predictive marker of an indi-
vidual’s risk for colorectal cancer.
 PEG1/MEST LOI in both extracted normal 
and tumor tissue specimens suggests that the detec-
tion of PEG1/MEST LOI in extracted normal tissue 
specimens may also pose a potential cancer risk in 
individuals for HNSCC.  IGF2 LOI has been found 
in 10% of normal individuals.  However, there are 
no reports indicating the incidence of PEG1/MEST 
LOI in normal individuals.  It will be necessary to 
clarify the incidence of PEG1/MEST LOI in nor-
mal individuals in order to elucidate its predictive 
value for an individual’s cancer risk for HNSCC.
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